| CAS NO: | 458-37-7 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 100mg | 电议 |
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 368.39 |
| Cas No. | 458-37-7 |
| Formula | C21H20O6 |
| Synonyms | Indian Saffron;Turmeric yellow;Natural Yellow 3;Diferuloylmethane |
| Solubility | ≥36.8 mg/mL in DMSO; insoluble in H2O; ≥3.5 mg/mL in EtOH with gentle warming and ultrasonic |
| Chemical Name | (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione |
| Canonical SMILES | O=C(CC(/C=C/C1=CC=C(O)C(OC)=C1)=O)/C=C/C2=CC=C(O)C(OC)=C2 |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
Curcumin是酪氨酸酶的抑制剂，IC50值为47 μM [1]。
Curcumin是具有抗癌功效的天然化合物。目前正在进行其对癌症预防效果的临床研究。这种抗癌功能有生化机制参与。Curcumin参与多种信号途径，包括转录因子、生长因子、炎性细胞因子、受体和酶。 I期临床试验测试了curcumin的毒性和耐受性，使用剂量为12 g/day的 curcumin没有毒性。Curcumin的生物利用度较差。在I / II期临床试验中，口服利用率约为1％，这阻碍了curcumin的临床应用[2]。
有研究表明curcumin降低了SH-SY5Y神经母细胞瘤细胞中Aβ40和Aβ42的产生，下调细胞中PS1和GSK-3β的表达，最终抑制Aβ的形成，在AD 病人中，curcumin是一种潜在的治疗剂[3]。
参考文献：
[1] Sachiko Shirota, Kouji Miyazaki, Ritsuo Aiyama, Minoru Ichioka and Teruo Yokokura. Tyrosinase inhibitors from crude drugs. Biol. Pharm. Bull. 1994, 17 (2): 266-269.
[2] Wungki Park, A.R.M Ruhul Amin, Zhuo Georgia Chen, and Dong M. Shin. New perspectives of curcumin in cancer prevention. Cancer Prev Res (Phila). 2013, 6(5): 387–400.
[3] Zhang Xiong, Zhang Hongmei, SiLu, LiYu. Curcumin mediates presenilin-1 activity to reduce β-amyloid production in a model of Alzheimer’s disease. Pharmacological Reports. 2013, 63: 1101-1108.
| Cell experiment:[1] | |
Cell lines | B16-R melanoma cells resistant to doxorubicin |
Reaction Conditions | 1 ~ 200 μM curcumin for 24, 36 or 48 h incubation |
Applications | Curcumin was found to be cytotoxicin vitrofor B16-R melanoma cells resistant to doxorubicin either cultivated as monolayers (1 ~ 100 μM) or grown in three-dimensional cultures (1 ~ 200 μM). The cytotoxic effect observed in the 2 culture types was related to the induction of programmed cell death. |
| Animal experiment:[1] | |
Animal models | Female B6D2F1 mice (6 ~ 8 weeks old) challenged subcutaneously with B16-R melanoma cells |
Dosage form | 25 mg/kg Once daily by intraperitoneal injection |
Applications | The combination treatment consisting of curcumin and soluble B16-R proteins resulted in substantial inhibition of growth of B16-R melanoma, whereas each treatment by itself showed little effect. Moreover, animals receiving the combination therapy exhibited an enhancement of their humoral anti-soluble B16-R protein immune response and a significant increase in their median survival time. Therefore, curcumin may provide a valuable tool for the development of a therapeutic combination against the melanoma. |
Note | The technical data provided above is for reference only. |
References: 1. Odot J, Albert P, Carlier A, et al. In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. International Journal of Cancer, 2004, 111(3): 381-387. | |
m.cnreagent.com